Cargando…

The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials

Background: Stable angina is a common condition with high morbidity and mortality rates. It has been reported that combining oral Chinese patent medicines (OCPMs) and Western medicine (WM) could potentially achieve a better effect than WM alone. However, the optimal OCPMs for stable angina remain co...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Peiying, Li, Zhishang, Chen, Li, Zeng, Jing, Zhao, Shuai, Tang, Yong, Huang, Bixuan, Guan, Hansu, Chen, Yan, Feng, Yuchao, Lei, Sisi, Wu, Qihua, Zhang, Haobo, Huang, Xiaoyan, Zeng, Linsheng, Liu, Yuxiang, Zeng, Zhongyi, Chen, Bojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428755/
https://www.ncbi.nlm.nih.gov/pubmed/36059992
http://dx.doi.org/10.3389/fphar.2022.918689
_version_ 1784779192800378880
author Huang, Peiying
Li, Zhishang
Chen, Li
Zeng, Jing
Zhao, Shuai
Tang, Yong
Huang, Bixuan
Guan, Hansu
Chen, Yan
Feng, Yuchao
Lei, Sisi
Wu, Qihua
Zhang, Haobo
Huang, Xiaoyan
Zeng, Linsheng
Liu, Yuxiang
Zeng, Zhongyi
Chen, Bojun
author_facet Huang, Peiying
Li, Zhishang
Chen, Li
Zeng, Jing
Zhao, Shuai
Tang, Yong
Huang, Bixuan
Guan, Hansu
Chen, Yan
Feng, Yuchao
Lei, Sisi
Wu, Qihua
Zhang, Haobo
Huang, Xiaoyan
Zeng, Linsheng
Liu, Yuxiang
Zeng, Zhongyi
Chen, Bojun
author_sort Huang, Peiying
collection PubMed
description Background: Stable angina is a common condition with high morbidity and mortality rates. It has been reported that combining oral Chinese patent medicines (OCPMs) and Western medicine (WM) could potentially achieve a better effect than WM alone. However, the optimal OCPMs for stable angina remain controversial and merit further empirical research. Methods: PubMed, Embase, Web of Science, Cochrane Library, Ovid-Medline, Clinical Trials.gov, China National Knowledge Infrastructure, Wanfang Database, Weipu Journal Database, and Chinese Biomedical Literature Database were all searched from inception to 13 March 2022. We employed Version 2 of the Cochrane risk-of-bias tool (ROB2) to assess the overall quality of the selected studies. We also used R 4.1.2 and STATA 14.0 software applications to perform network meta-analysis, followed by sensitivity and subgroup analysis. Results: A total of 179 randomized controlled trials with 16,789 patients were included. The selected trials were all assessed as some concerns. OCPMs combined with WM had a better treatment effect than WM alone. In terms of the effective clinical rate, a significant increase was detected for Qishen Yiqi dripping pill (QSYQ)+WM as compared with Shensong Yangxin capsule (SSYX)+WM, Shexiang Baoxin pill (SXBX)+WM, Tongxinluo capsule (TXL)+WM, Xuefu Zhuyu capsule (XFZY)+WM, Qiliqiangxin capsule (QLQX)+WM, Naoxintong capsule (NXT)+WM, Fufang Danshen dripping pill (FFDS)+WM, and Danlou tablet (DL)+WM. QSYQ + WM had the highest-ranking probability (98.12%). Regarding the effective rate in ECG, QSYQ + WM was superior to SXBX + WM, TXL + WM, DL + WM, FFDS + WM, and NXT + WM. QSYQ + WM ranked first (94.21%). In terms of weekly frequency of angina, QLQX + WM obtained a better effect than FFDS + WM, Kuanxiong aerosol (KXQW)+WM, NXT + WM, QLQX + WM, SSYX + WM, SXBX + WM, and TXL + WM. QLQX + WM ranked first (100.00%). Regarding the duration of an angina attack, KXQW + WM was superior to SSYX + WM; KXQW + WM ranked first (95.71%). Adverting to weekly nitroglycerin usage, TXL + WM had the highest-ranking probability (82.12%). Referring to cardiovascular event rate, DL + WM had the highest effect (73.94%). Additionally, SSYX + WM had the lowest rate of adverse drug reactions (1.14%). Conclusion: OCPMs combined with WM had a higher efficacy. QSYQ + WM, QLQX + WM, KXQW + WM, TXL + WM, DL + WM, SSYX + WM, and SXBX + WM merit further investigation. SXBX + WM is presumably the optimal treatment prescription for both clinically effective and cardiovascular event rates. Further high-quality empirical research is needed to confirm the current results. Systematic Review Registration: URL = https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=316534, CRD 42022316534
format Online
Article
Text
id pubmed-9428755
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94287552022-09-01 The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials Huang, Peiying Li, Zhishang Chen, Li Zeng, Jing Zhao, Shuai Tang, Yong Huang, Bixuan Guan, Hansu Chen, Yan Feng, Yuchao Lei, Sisi Wu, Qihua Zhang, Haobo Huang, Xiaoyan Zeng, Linsheng Liu, Yuxiang Zeng, Zhongyi Chen, Bojun Front Pharmacol Pharmacology Background: Stable angina is a common condition with high morbidity and mortality rates. It has been reported that combining oral Chinese patent medicines (OCPMs) and Western medicine (WM) could potentially achieve a better effect than WM alone. However, the optimal OCPMs for stable angina remain controversial and merit further empirical research. Methods: PubMed, Embase, Web of Science, Cochrane Library, Ovid-Medline, Clinical Trials.gov, China National Knowledge Infrastructure, Wanfang Database, Weipu Journal Database, and Chinese Biomedical Literature Database were all searched from inception to 13 March 2022. We employed Version 2 of the Cochrane risk-of-bias tool (ROB2) to assess the overall quality of the selected studies. We also used R 4.1.2 and STATA 14.0 software applications to perform network meta-analysis, followed by sensitivity and subgroup analysis. Results: A total of 179 randomized controlled trials with 16,789 patients were included. The selected trials were all assessed as some concerns. OCPMs combined with WM had a better treatment effect than WM alone. In terms of the effective clinical rate, a significant increase was detected for Qishen Yiqi dripping pill (QSYQ)+WM as compared with Shensong Yangxin capsule (SSYX)+WM, Shexiang Baoxin pill (SXBX)+WM, Tongxinluo capsule (TXL)+WM, Xuefu Zhuyu capsule (XFZY)+WM, Qiliqiangxin capsule (QLQX)+WM, Naoxintong capsule (NXT)+WM, Fufang Danshen dripping pill (FFDS)+WM, and Danlou tablet (DL)+WM. QSYQ + WM had the highest-ranking probability (98.12%). Regarding the effective rate in ECG, QSYQ + WM was superior to SXBX + WM, TXL + WM, DL + WM, FFDS + WM, and NXT + WM. QSYQ + WM ranked first (94.21%). In terms of weekly frequency of angina, QLQX + WM obtained a better effect than FFDS + WM, Kuanxiong aerosol (KXQW)+WM, NXT + WM, QLQX + WM, SSYX + WM, SXBX + WM, and TXL + WM. QLQX + WM ranked first (100.00%). Regarding the duration of an angina attack, KXQW + WM was superior to SSYX + WM; KXQW + WM ranked first (95.71%). Adverting to weekly nitroglycerin usage, TXL + WM had the highest-ranking probability (82.12%). Referring to cardiovascular event rate, DL + WM had the highest effect (73.94%). Additionally, SSYX + WM had the lowest rate of adverse drug reactions (1.14%). Conclusion: OCPMs combined with WM had a higher efficacy. QSYQ + WM, QLQX + WM, KXQW + WM, TXL + WM, DL + WM, SSYX + WM, and SXBX + WM merit further investigation. SXBX + WM is presumably the optimal treatment prescription for both clinically effective and cardiovascular event rates. Further high-quality empirical research is needed to confirm the current results. Systematic Review Registration: URL = https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=316534, CRD 42022316534 Frontiers Media S.A. 2022-08-17 /pmc/articles/PMC9428755/ /pubmed/36059992 http://dx.doi.org/10.3389/fphar.2022.918689 Text en Copyright © 2022 Huang, Li, Chen, Zeng, Zhao, Tang, Huang, Guan, Chen, Feng, Lei, Wu, Zhang, Huang, Zeng, Liu, Zeng and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Huang, Peiying
Li, Zhishang
Chen, Li
Zeng, Jing
Zhao, Shuai
Tang, Yong
Huang, Bixuan
Guan, Hansu
Chen, Yan
Feng, Yuchao
Lei, Sisi
Wu, Qihua
Zhang, Haobo
Huang, Xiaoyan
Zeng, Linsheng
Liu, Yuxiang
Zeng, Zhongyi
Chen, Bojun
The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials
title The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials
title_full The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials
title_fullStr The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials
title_full_unstemmed The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials
title_short The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials
title_sort comparative effects of oral chinese patent medicines combined with western medicine in stable angina: a systematic review and network meta-analysis of 179 trials
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428755/
https://www.ncbi.nlm.nih.gov/pubmed/36059992
http://dx.doi.org/10.3389/fphar.2022.918689
work_keys_str_mv AT huangpeiying thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT lizhishang thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT chenli thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT zengjing thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT zhaoshuai thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT tangyong thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT huangbixuan thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT guanhansu thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT chenyan thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT fengyuchao thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT leisisi thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT wuqihua thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT zhanghaobo thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT huangxiaoyan thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT zenglinsheng thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT liuyuxiang thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT zengzhongyi thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT chenbojun thecomparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT huangpeiying comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT lizhishang comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT chenli comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT zengjing comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT zhaoshuai comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT tangyong comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT huangbixuan comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT guanhansu comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT chenyan comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT fengyuchao comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT leisisi comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT wuqihua comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT zhanghaobo comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT huangxiaoyan comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT zenglinsheng comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT liuyuxiang comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT zengzhongyi comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials
AT chenbojun comparativeeffectsoforalchinesepatentmedicinescombinedwithwesternmedicineinstableanginaasystematicreviewandnetworkmetaanalysisof179trials